Acknowledgment: This story is sponsored by GSK and is promoted through the Patient Worthy Collaborative Content program. We only publish content that embodies our mission of providing relevant, vetted, and valuable information to the patient community.

Facing an Endometrial Cancer Diagnosis

A diagnosis of endometrial cancer can feel overwhelming, bringing with it a whirlwind of emotions, uncertainty, and difficult decisions.  Yet, amidst the confusion, many also discover a moment of clarity — a powerful turning point sparked by the courage to share their story to help others.  By transforming their personal experiences into messages of hope and inspiration, they find renewed strength, purpose, and a desire to make a difference.  This journey, though challenging, can become a source of illumination, guiding patients toward deeper connections with others and inspiring them to transform their own experience into something profoundly meaningful.

That’s what the Ambassador Program is all about: offering a platform for those who’ve walked this path to transform their lived experience into hope and guidance for others.  Through education and outreach, ambassadors share valuable insights and may help others navigate the darkness ahead.  They often become voices of encouragement and reassurance, showing that no one should have to face endometrial cancer alone.

What is Advanced or Returned Endometrial Cancer?

Endometrial cancer begins in the tissue that lines the uterus and is the most common gynecologic malignancy in the US, with more than 62,000 diagnoses expected in 2025.

Advanced endometrial cancer is when the cancer has spread outside the uterus.  Returned endometrial cancer is when the cancer has come back after treatment.  Roughly speaking about 1 in 4 people diagnosed with endometrial cancer experience advanced or returned cancer.

What is the Ambassador Program?

The Ambassador Program connects patients, caregivers, and advocates who want to share their experiences with endometrial cancer to help others.  Whether it’s one-on-one conversations, community events, or online outreach, Ambassadors may help provide:

• • Patient Education− Insights on their own treatment decisions, personal experience with their endometrial cancer journey, and perspectives on their daily life.
  • Community Outreach− Raising awareness and building connections.
  • Advocacy− Empowering patient voices to influence research and representation.

Why Your Story Matters

Real Support.  Real Impact. 

No pamphlet or website can replace hearing from someone who’s lived it.  As an ambassador, you might be the voice that helps someone feel less alone.

Practical Tips That Matter

From managing appointments to navigating daily life, Ambassadors share the real-world advice that may help make an impact.

Spreading Hope

A fulfilling life can be possible — even after an advanced or returned cancer diagnosis.  Ambassadors are often living proof of that possibility that there is hope.

Fighting Stigma

Gynecologic cancers are often misunderstood.  Sharing your story helps normalize the conversation and challenge the stigma.

What You May Gain as an Ambassador

• • Community and Connection− Meet others who may understand – and build friendships that last.
  • Empowerment Through Knowledge− Stay informed on the latest GSK research.
  • Leaving a Legacy− Inspire others and possibly help shape a more supportive future.

Admission of applicants in the program is at the discretion of GSK.

When you share your story, you do more than speak—you light the way for someone else.

Have you been prescribed this treatment option?

There’s something deeply powerful about the stories patients share with one another.  In those words, there’s real hope, raw and honest, born from lived experience.  There’s comfort in knowing someone else has walked a similar path.

If you have endometrial cancer and are taking JEMPERLI (dostarlimab-gxly; injection 500mg), you can illuminate your journey for others.

Approved Uses

JEMPERLI is a prescription medicine used to treat adults with:

• a kind of uterine cancer called endometrial cancer (EC)
  • JEMPERLI may be used in combination with the chemotherapy medicines, carboplatin and paclitaxel, and then after that JEMPERLI may be used alone:
    • when your cancer has spread outside your uterus (advanced) or,
    • your cancer has returned.
  • JEMPERLI may be used alone:
    • when a laboratory test shows that your tumor is mismatch repair deficient (dMMR), and
    • your cancer has returned, or it has spread (advanced EC), and
    • you have received chemotherapy that contains platinum and it did not work or is no longer working, and
    • your cancer cannot be treated by surgery or radiation.

It is not known if JEMPERLI is safe and effective in children.

Important Safety Information

JEMPERLI is a medicine that may treat certain cancers by working with your immune system. JEMPERLI can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended.

Call or see your healthcare provider (HCP) right away if you develop any new or worsening signs or symptoms, including:

Lung problems. Signs and symptoms may include cough, shortness of breath, or chest pain.

Intestinal problems. Signs and symptoms may include diarrhea or more bowel movements than usual; stools that are black, tarry, sticky, or have blood or mucus; or severe stomach-area (abdomen) pain or tenderness.

Liver problems. Signs and symptoms may include yellowing of your skin or the whites of your eyes, severe nausea or vomiting, pain on the right side of your stomach area (abdomen), dark urine (tea colored), or bleeding or bruising more easily than usual.

Hormone gland problems. Signs and symptoms may include headaches that will not go away or unusual headaches, eye sensitivity to light, eye problems, rapid heartbeat, increased sweating, extreme tiredness, weight gain or weight loss, feeling more hungry or thirsty than usual, urinating more often than usual, hair loss, feeling cold, constipation, your voice gets deeper, dizziness or fainting, changes in mood or behavior such as decreased sex drive, irritability, or forgetfulness.

Kidney problems. Signs and symptoms may include change in the amount or color of your urine, blood in your urine, swelling in your ankles, or loss of appetite.

Skin problems. Signs and symptoms may include rash; itching; skin blistering or peeling; swollen lymph nodes; painful sores or ulcers in your mouth or in your nose, throat, or genital area; fever or flu-like symptoms.

Problems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with JEMPERLI. Call or see your HCP right away for any new or worse signs or symptoms. Signs and symptoms may include chest pain, irregular heartbeat, shortness of breath, swelling of ankles; confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs; double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight; persistent or severe muscle pain or weakness, muscle cramps; low red blood cells, bruising.

Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness, feel like passing out, fever, back or neck pain.

Rejection of a transplanted organ. Your HCP should tell you what signs and symptoms you should report and monitor you, depending on the type of organ transplant that you have had.

Complications, including graft-versus-host-disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with JEMPERLI. Your HCP will monitor you for these complications.

Getting medical treatment right away may help keep these problems from becoming more serious. Your HCP will check you for these problems during treatment with JEMPERLI and may treat you with corticosteroid or hormone replacement medicines. If you have severe side effects, your HCP may also need to delay or completely stop treatment with JEMPERLI.

Before receiving JEMPERLI, tell your HCP about all of your medical conditions, including immune system problems such as Crohn’s disease, ulcerative colitis, or lupus; received an organ transplant; have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic); have received radiation treatment to your chest area; have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome.

If you are pregnant or plan to become pregnant, tell your HCP. JEMPERLI can harm your unborn baby. If you are able to become pregnant, your HCP will give you a pregnancy test before you start treatment. Use an effective birth control method during treatment and for 4 months after your last dose of JEMPERLI. Tell your HCP right away if you become pregnant or think you may be pregnant during treatment with JEMPERLI.

If you are breastfeeding or plan to breastfeed, tell your HCP. It is not known if JEMPERLI passes into your breast milk. Do not breastfeed during treatment with JEMPERLI and for 4 months after your last dose.

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of JEMPERLI when given with carboplatin and paclitaxel include nerve problems in your arms, hands, legs, and feet; tiredness; nausea; hair loss; joint pain; rash; constipation; diarrhea; stomach-area (abdomen) pain; shortness of breath; decreased appetite; urinary tract infections; vomiting.

The most common side effects of JEMPERLI when used alone include tiredness and weakness, low red blood cell count (anemia), diarrhea, nausea, constipation, vomiting.

These are not all the possible side effects of JEMPERLI.  Call your HCP for medical advice about side effects.  You are encouraged to report negative side effects of prescription drugs to the FDA.  Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.  You may also report negative side effects to GSK at https://gsk.pubic.reportum.com or 1-888-825-5249.

Please see full Prescribing Information, including Medication Guide for patients.

How Does It Work?

JEMPERLI is an immunotherapy. In endometrial cancer, cancer cells can hide from the immune system. Cells are then able to grow and spread. JEMPERLI may prevent cancer cells from hiding so your immune system can find and attack them.

Why Is Biomarker Testing Important?

JEMPERLI is FDA-approved specifically for certain types of endometrial cancer, including those that are  mismatch repair deficient (dMMR). A biomarker test can determine if your tumor is dMMR —an important step that may help guide your treatment plan.

Talk to your care team about biomarker testing.

A biomarker is a molecule found in blood, tissue, or other cells in the body that show if a condition, process, or disease is normal or abnormal. Biomarkers that are important in endometrial cancer are MMR and MSI. MMR and MSI stand for mismatch repair and microsatellite instability. Normally, the MMR system fixes mistakes that can occur in the genes of your cancer. If the MMR system is working properly, errors are corrected and the genes remain stable. Some cancers have a defective or deficient MMR system, or dMMR, which is not able to correct errors in the genes. This causes errors to build up, making the genes unstable.

National guidelines recommend MMR/MSI testing if you have endometrial cancer. Ask your doctor for information on biomarker testing. It’s a key part of creating a personalized approach to care.

To learn more about JEMPERLI, talk to a doctor or please visit:
🔗 www.jemperli.com

The conduct of the program, including but not limited to inclusion of ambassadors and any requirements for additional agreements, is controlled by GSK.

Trademarks are owned by or licensed to the GSK group of companies.

©2025 GSK or licensor.

PMUS-DSTADVR250002 August 2025

Produced in USA.